The manufacturer needs you to present your results on the drug trial in graphic form for their
FDA application. Recall that the NT71C drug decreased patients' hemoglobin counts by
0.47g/dL each week, and that a healthy patient has a hemoglobin count of 14.2g/dL. Graph
the hemoglobin count of a patient that takes NT71C without iron supplements for 10 weeks.
Does the patient's hemoglobin count fall to a dangerous 11.4g/dL or less? If so, circle the
point where the patient's hemoglobin count becomesdangerous and identify the time
(x-position) on the graph.
